BioDlink International (1875) Stock Overview
An investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
1875 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
BioDlink International Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.20 |
| 52 Week High | HK$4.66 |
| 52 Week Low | HK$1.52 |
| Beta | 0.22 |
| 1 Month Change | 68.00% |
| 3 Month Change | 118.75% |
| 1 Year Change | 133.33% |
| 3 Year Change | 92.66% |
| 5 Year Change | -0.94% |
| Change since IPO | -32.91% |
Recent News & Updates
Recent updates
Is BioDlink International (HKG:1875) Using Too Much Debt?
Nov 18
Benign Growth For TOT BIOPHARM International Company Limited (HKG:1875) Underpins Its Share Price
Jul 24TOT BIOPHARM International Company Limited's (HKG:1875) CEO Will Probably Find It Hard To See A Huge Raise This Year
Jun 13Is TOT BIOPHARM International (HKG:1875) A Risky Investment?
Apr 10TOT BIOPHARM International Company Limited's (HKG:1875) Low P/S No Reason For Excitement
Dec 18We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation
Jun 07The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More
May 21Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt
May 18Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Jul 27An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
Mar 26Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Feb 03Shareholder Returns
| 1875 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -1.2% | 5.5% | 1.6% |
| 1Y | 133.3% | 115.1% | 28.0% |
Return vs Industry: 1875 exceeded the Hong Kong Biotechs industry which returned 115.1% over the past year.
Return vs Market: 1875 exceeded the Hong Kong Market which returned 28% over the past year.
Price Volatility
| 1875 volatility | |
|---|---|
| 1875 Average Weekly Movement | 22.4% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in HK Market | 14.0% |
| 10% least volatile stocks in HK Market | 2.9% |
Stable Share Price: 1875's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1875's weekly volatility has increased from 13% to 22% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 604 | n/a | www.biodlink.com |
BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule for the treatment of newly diagnosed glioblastoma multiforme or anaplastic astrocytoma that recurs or progresses after conventional treatment.
BioDlink International Company Limited Fundamentals Summary
| 1875 fundamental statistics | |
|---|---|
| Market cap | HK$3.25b |
| Earnings (TTM) | HK$8.22m |
| Revenue (TTM) | HK$1.21b |
Is 1875 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1875 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.07b |
| Cost of Revenue | CN¥308.30m |
| Gross Profit | CN¥758.56m |
| Other Expenses | CN¥751.30m |
| Earnings | CN¥7.26m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0094 |
| Gross Margin | 71.10% |
| Net Profit Margin | 0.68% |
| Debt/Equity Ratio | 54.1% |
How did 1875 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 12:48 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioDlink International Company Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Xin Qiu Lin | Guoyuan Securities (HK) Ltd |
| Yue-Kwong Lui | Jefferies LLC |